‹ ›
MYP_133808
← PREVIOUS NEXT → BACK
Basic Information
D-MART-1
Anticancer
Binding / Molecular interaction ▸ Binding activity
Immunology ▸ Immunomodulation ▸ Immunogenic
Immunology ▸ MHC/HLA binding
Standard
9 amino acids
C37H67N9O11
Standard
Sequence
AAGIGILTV
Physicochemical Analysis
813.98 Da
5.57
-0.20
-0.39
-0.0227
2.12
0.08
0.78
11.42
184.44
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
316.35
-2.25
11.0
11.0
25.0
57.0
0.0
8.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0298449 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
None
Bio-Activity Profile
Immunogenic HLA-binding
inhibition of binding of a standard peptide to HLA-A*0201 molecules is 35μM
35 μM
IC50
VMM5 cytotoxic T-lymphocyte line incubated in human plasma, in vitro; Stability increased seconds
PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0302310 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Melan-A peptide
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Immunogenic HLA-binding
0.004 μM
EC50
Serum (human), in vitro; 300 s
RECORD: Rec_0321451 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MART-1
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Anticancer
Human plasma: Stability increased
PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0344972 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MART-1
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
PEGylation
Bio-Activity Profile
Anticancer
Human plasma: Stability increased
PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
RECORD: Rec_0349143 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Amidation
Bio-Activity Profile
Immunogenic HLA-binding
inhibition of binding of a standard peptide to HLA-A*0201 molecules is 7μM
7 μM
IC50
VMM5 cytotoxic T-lymphocyte line incubated in human plasma, in vitro; Stability increased seconds
PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 3 of 4